Dr. Jacqueline Lui, President of Eagle IP Limited, gave a talk titled “IP Protection Strategies for Drugs” at the Hong Kong Productivity Council for the forum “如何利用防偽技術保護藥品商標及品牌研討會(II)”.
我们的过去活动
Recommended Insights
New Remedy in China for Fixing "Errors" in a Patent Application: Incorporation by Reference
2024年3月21日Background As mentioned in our earlier article, the Implementation Regulations of the Chinese Patent Law (“Regulations”, similar to the CFR in the US) were approved in November, and the CNIPA finally made public the full text of the Regulations just before the arrival of the New Year. At the same time, the CNIPA also released the new […]
阅读更多 >
Major and Exciting Changes to China’s Patent Law [Fourth Amendment to China's Patent Law]
2019年2月20日Major changes are on the horizon for China’s Patent Law, which will see an overhaul in many areas as early as this year (2019). On January 4, 2019, the National People’s Congress in China published the latest draft of the Fourth Amendment to China’s Patent Law. Several draft amendments have been released for public comment […]
阅读更多 >
Burden Shift: CNIPA Requires Applicant to “Prove” that Post-Filing Data is not Fake Data
2025年4月1日“Good Faith” is a challenging concept that brings with it the nuances of a particular jurisdiction’s ideas about honesty, moral values, and societal expectations. Most patent laws around the world include good faith requirements – especially in matters involving the legal and the medical profession – and China is no exception. So what’s the standard? […]
阅读更多 >
Foreign companies transferring IP out of China: things to know
2018年10月25日Inventions made in China Most foreign companies with R&D sites in China are aware of the fact that inventors having inventions made in China have to obtain permission before they can file patent applications outside of China for these Chinese inventions. It doesn’t matter if the owner of the business is a foreign entity. Patent […]
阅读更多 >